In March 2018 we started work on the Australian Environmental Microbiome Research Data Cloud...find out more
Melbourne Bioinformatics is one of 80 partners across Australia and internationally who are...find out more
A Dutch study published in Genetics in Medicine on 4 February 2016 applies a cost analysis to the...find out more
Users on our systems work on a range of projects across the life sciences. Current highlights from some high profile researchers and their projects include:
Well covered in the media in December was the publication in Nature Ecology & Evolution of the genome of the extinct Tasmanian tiger or thylacine. The research was led by Assoc Prof Andrew Pask from the School of BioSciences, The University of Melbourne, Victoria, Australia, with collaborators from Museums Victoria; the Institute of Experimental Pathology (ZMBE), University of Münster, Germany; the Australian Centre for Ancient DNA, University of Adelaide, South Australia; and, the Institute for Systems Genomics and Department of Molecular and Cell Biology, University of Connecticut, USA.
"The thylacine and the dog [or wolf] is the closest example of convergent evolution that we’ve ever seen measured between any two species", said Assoc Prof Pask. "When two animals that are not closely related evolved to look the same – that is really astounding."
The team's research data on unique Australian marsupials is of interest to the global life sciences research community and we hope that our involvement in the EMBL-ABR network can how help to make it more readily accessible.
Full story - https://pursuit.unimelb.edu.au/articles/secrets-from-beyond-extinction-the-tasmanian-tiger.
Professor Tony Burkitt, Research Director of Bionic Vision Australia (BVA) and Professor of Engineering at the University of Melbourne, has been using our systems to examine the effect of electrical stimulation upon the neurons in the retina, with the aim of developing improved vision processing algorithms for retinal implants. Over 2016 this research program had a number of important achievements, mostly in the development of more refined computational models and new signal processing techniques.
Earlier this year the commercial arm of BVA, Bionic Vision Technologies, announced the commercialisation of the first generation of its technology and it will be ongoing modelling and refining of techniques which will contribute further to BVA’s outcomes. Prof Burkitt said, “It's great to see this technology transitioning into clinical and commercial use, and we're excited about what the future holds for this area!”
Read the news announcement here: http://bionicvis.com/wp-content/uploads/2017/04/03APR2017_BVT-media-release.pdf